Literature DB >> 1581912

Inherited p53 gene mutations in breast cancer.

D Sidransky1, T Tokino, K Helzlsouer, B Zehnbauer, G Rausch, B Shelton, L Prestigiacomo, B Vogelstein, N Davidson.   

Abstract

Recent evidence has implicated germ-line mutations of the p53 gene as the cause of cancer susceptibility in the Li-Fraumeni syndrome, associated with the development of breast cancer and other neoplasms. Furthermore, somatic mutations of the p53 gene have been detected in a high percentage of non-familial breast cancers. We therefore sought to identify potential carriers of p53 gene mutations in a cohort of patients with early onset breast cancer. We examined 126 consecutive patients who developed breast cancer at or before the age of 40 for mutations of p53 within conserved regions of the gene. One patient with an inherited germ-line mutation of the p53 gene was identified but the functional significance of this mutation was not clear. It thus appears that only a small percentage of patients with breast cancer under the age of 40 carry germ-line mutations of the p53 gene, an observation which has implications for potential screening and risk assessment in such patients.

Entities:  

Mesh:

Year:  1992        PMID: 1581912

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  67 in total

1.  A highly accurate, low cost test for BRCA1 mutations.

Authors:  N J van Orsouw; R K Dhanda; Y Elhaji; S A Narod; F P Li; C Eng; J Vijg
Journal:  J Med Genet       Date:  1999-10       Impact factor: 6.318

Review 2.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

3.  Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.

Authors:  S Chaudhuri; A Cariappa; M Tang; D Bell; D A Haber; K J Isselbacher; D Finkelstein; D Forcione; S Pillai
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 4.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

5.  Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.

Authors:  Judy Mouchawar; Christopher Korch; Tim Byers; Todd M Pitts; Efang Li; Margaret R E McCredie; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

6.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

7.  Unique tissue-specific level of DNA nucleotide excision repair in primary human mammary epithelial cultures.

Authors:  Jean J Latimer; Tariq Nazir; Lisa C Flowers; Michael J Forlenza; Kelly Beaudry-Rodgers; Crystal M Kelly; Julie A Conte; Kenneth Shestak; Amal Kanbour-Shakir; Stephen G Grant
Journal:  Exp Cell Res       Date:  2003-11-15       Impact factor: 3.905

8.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology.

Authors:  B Newman; P G Moorman; R Millikan; B F Qaqish; J Geradts; T E Aldrich; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

10.  Ha-ras rare alleles in breast cancer susceptibility.

Authors:  K Conway; S Edmiston; D B Fried; B S Hulka; P A Garrett; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.